Showing results (161-170 of 500) with videos related to
Sort By:
Pageof 50
The Journal of Clinical Investigation|September 19, 2001
Signaling through CD28 and CTLA-4 controls two distinct forms of T cell anergyA D Wells, M C Walsh, J A Bluestone, et al.Proceedings of the National Academy of Sciences of the United States of America|February 1, 1991
In vivo T-cell activation by staphylococcal enterotoxin B prevents outgrowth of a malignant tumorK A Newell, J D Ellenhorn, D S Bruce, et al.Immunology Today|July 1, 1994
The B7 and CD28 receptor familiesC H June, J A Bluestone, L M Nadler, et al.Blood|May 15, 1996
Murine gamma/delta-expressing T cells affect alloengraftment via the recognition of nonclassical major histocompatibility complex class Ib antigensB R Blazar, P A Taylor, J A Bluestone, et al.Blood|June 1, 1992
Effects of anti-CD3 monoclonal antibody on engraftment of T-cell-depleted bone marrow allografts in mice: host T-cell suppression, growth factors, and spaceK Hiruma, R Hirsch, M Patchen, et al.The Journal of Experimental Medicine|June 2, 1997
T cell receptor-gamma/delta cells protect mice from herpes simplex virus type 1-induced lethal encephalitisR Sciammas, P Kodukula, Q Tang, et al.European Journal of Immunology|March 29, 2002
The role of CTLA-4 in induction and maintenance of peripheral T cell toleranceTodd N Eagar, Nitin J Karandikar, Jeffrey A Bluestone, et al.The Journal of Experimental Medicine|November 17, 2005
Sequential development of interleukin 2-dependent effector and regulatory T cells in response to endogenous systemic antigenBirgit Knoechel, Jens Lohr, Estelle Kahn, et al.Nature Reviews. Immunology|July 27, 2007
What does the future hold for cell-based tolerogenic therapy?Jeffrey A Bluestone, Angus W Thomson, Ethan M Shevach, et al.Nature Reviews. Drug Discovery|September 22, 2019
Next-generation regulatory T cell therapyLeonardo M R Ferreira, Yannick D Muller, Jeffrey A Bluestone, et al.Pageof 50